Oncimmune notes the ERJ has published positive results from the ECLS trial
Vox Markets
RNS Newswire
07:10, 31st July 2020

Oncimmune Holdings plc (AIM: ONC.L) FOLLOW, announces that The European Respiratory Journal has published the peer reviewed results from the Early detection of Cancer of the Lung Scotland ("ECLS") trial. 

The European Respiratory Journal is a leading lung disease focused scientific publication and flagship journal of the European Respiratory Society 

The paper titled 'Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging' will be replicated in print before Q3 2020, evaluates the effectiveness of Oncimmune's EarlyCDT Lung test in reducing the incidence of patients presenting with late-stage lung cancer at diagnosis. 

The paper concludes that blood-based biomarker panels, such as the EarlyCDT Lung test, followed by low dose CT, can detect stage I/II lung cancers earlier than standard clinical practice. 

In Scotland, lung cancer affects more than 5,000 people every year of which approximately 4,000 will die of the disease, usually because the diagnosis is made too late for curative treatment. 

Earlier diagnosis means that more patients should benefit from newer, more effective, chemotherapy, surgery and radiotherapy, and so reduce the impact of this disease. 

The Trial 

To determine whether the EarlyCDT Lung blood test reduced the incidence of patients with stage III/IV lung cancer, the ECLS trial in 12,208 patients compared the use of the EarlyCDT Lung blood test followed by low dose computerised tomography ("CT") scanning to standard clinical practice.  

The ECLS trial is believed to be the largest randomised controlled trial for the detection of cancer using blood-based biomarkers conducted anywhere in the world to date and demonstrated a 36% reduction in late stage diagnoses of lung cancer.  

In addition, the ECLS trial results indicated a lower rate of both all deaths and lung cancer-related deaths among people in the intervention arm of the trial after two years compared with people in the control group.  

This suggests that the EarlyCDT Lung test followed by CT imaging could produce a mortality benefit: the 3 year follow up data - scheduled to be analysed imminently - will be critical in substantiating this. 

The ECLS trial was delivered by the Universities of Dundee and St Andrews with NHS Tayside, and co-funded by Oncimmune, the Scottish Chief Scientist Office and the Scottish Government. 

Further follow-up analyses on this unique, globally significant cohort will be performed after 5 and 10 years. 

Shares in ONC have soared over the past three months from 80p to close at 129p yesterday. 

Dr Adam M Hill, CEO of Oncimmune, said: "We are delighted to see the ECLS trial data published in the European Respiratory Journal, as it both expands the availability of these results in the wider pulmonology community and confirms through peer review the findings and clinical potential of EarlyCDT Lung. The ECLS trial data was presented on the Presidents podium at WCLC 2019 in Barcelona last year. This publication will unlock discussions with a number of health systems on implementation, many of whom have been looking forward to the validation that this much anticipated peer review brings. We and our partners will now work at speed with health authorities in the UK and further afield to roll out EarlyCDT Lung more widely, ahead of a fuller analysis of the survival benefit of EarlyCDT Lung." 

Professor Frank Sullivan, Professor of Primary Care Medicine at the University of St. Andrews, the Chief Investigator for the ECLS trial, said: "I hope that the results of this trial will have globally significant implications for the early detection of lung cancer by showing how a simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher." 

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles